NCT04852861View on ClinicalTrials.gov

COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

July 31, 2021

Study Completion Date

September 30, 2022

Conditions
Covid19
Interventions
DIAGNOSTIC_TEST

immunogenicity after first and second dose

Humoral and cellulair immunity after first and second dose of the different vaccines administrated.

Trial Locations (1)

2000

Mensura EDPB, Antwerp

All Listed Sponsors
collaborator

Mensura EDPB

UNKNOWN

collaborator

Institute of Tropical Medicine, Belgium

OTHER

collaborator

Erasme University Hospital

OTHER

lead

Sciensano

OTHER_GOV